NHS Grampian
Formulary Group Decisions for SMC advice published April 2024 to March 2025

This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April 2024 to March 2025.

For the latest Formulary Group decisions see the Grampian Area Formulary website.

April 2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
amivantamab 350mg concentrate for solution for infusion (Rybrevant®)	2768	In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).	Not routinely available as not recommended for use in NHS Scotland, SMC 2768 https://scottishmedicines.org.uk/media/9020/amivantamab-rybrevant-non-sub-final-feb-2025-for-website.pdf	18/03/2025
atezolizumab 840mg, 1,200mg concentrate for solution for infusion, 1,875mg solution for injection (Tecentriq®)	2769	As monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2769 https://scottishmedicines.org.uk/media/9021/atezolizumab-tecentriq-non-sub-final-feb-2025-for-website.pdf	18/03/2025
axicabtagene ciloleucel 0.4 – 2 x 10^8 cells dispersion for infusion (Yescarta®)	2695	For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Routinely available in line with national guidance, SMC 2695 https://scottishmedicines.org.uk/media/8728/axicabtagene-yescarta-resubmission-final-oct-2024-for-website.pdf	19/11/2024
Bevespi Aerosphere® 7.2micrograms/5micrograms pressurised inhalation, suspension (glycopyrronium/formoterol fumarate)	2652	As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Not routinely available as there is a local preference for alternative medicines	16/04/2024
Biktarvy® 30mg/120mg/15mg film-coated tablet (bictegravir/emtricitabine/ tenofovir alafenamide)	2760	Treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14kg to less than 25kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.	Not routinely available as not recommended for use in NHS Scotland, SMC 2760 https://scottishmedicines.org.uk/media/8859/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-non-sub-final-dec-2024-for-website.pdf	21/01/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
cabotegravir 600mg prolonged-release suspension for injection, 30mg film coated tablets (Apretude®)	2718	Cabotegravir prolonged-release injection: in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35kg. Cabotegravir tablets: in combination with safer sex practices for short term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35kg. Cabotegravir tablets may be used as: - oral lead-in to assess tolerability of cabotegravir prior to administration of long acting cabotegravir injection. - oral PrEP for individuals who will miss planned dosing with cabotegravir injection. **SMC restriction**: Adults and adolescents (weighing at least 35kg) at high risk of sexually acquired HIV who are eligible for PrEP, including oral PrEP, but for whom oral PrEP is not appropriate to meet their HIV prevention needs.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/02/2025
cabozantinib 20mg, 40mg, 60mg film-coated tablets (Cabozantinib Ipsen)	2754	As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/03/2025
cemiplimab 350mg concentrate for solution for infusion (Libtayo®)	2719	As monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/02/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
cemiplimab 350mg concentrate for solution for infusion (Libtayo®)	2724	In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: - locally advanced NSCLC who are not candidates for definitive chemoradiation, or - metastatic NSCLC.	Not routinely available as not recommended for use in NHS Scotland, SMC 2724 https://scottishmedicines.org.uk/media/8639/cemiplimab-libtayo-non-sub-final-sept-2024-for-website.pdf	15/10/2024
ciclosporin 0.9mg/mL eye drops solution in single-dose container (Cequa®)	2739	Treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears. **SMC restriction**: severe keratitis in adult patients with Dry Eye Disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
clostridium botulinum neurotoxin type A 50units, 100units, 200units (Xeomin®)	2680	Focal spasticity of the lower limb affecting the ankle joint.	Not routinely available as not recommended for use in NHS Scotland, SMC 2680 https://www.scottishmedicines.org.uk/media/8380/clostridium-botulinum-neurotoxin-type-a-xeomin-non-sub-final-may-2024-for-website.pdf	18/06/2024
crovalimab 340mg solution for injection/infusion (Piasky®)	2728	As monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40kg and above with paroxysmal nocturnal haemoglobinuria (PNH) in patients: - with haemolysis with clinical symptom(s) indicative of high disease activity. - who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months. **SMC restriction**: under the advice of the national PNH service	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
dabrafenib 10mg dispersible tablets (Finlee®)	2667	In combination with trametinib (Spexotras®) for: - the treatment of paediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy - the treatment of paediatric patients aged 1 year and older with high-grade glioma with a BRAF V600E mutation who have received at least one prior radiation and / or chemotherapy treatment	Routinely available in line with national guidance, SMC 2667 https://scottishmedicines.org.uk/media/8575/dabrafenib-finlee-final-august-2024-for-website.pdf Updates decision 17/09/24	15/04/2025
danicopan 50mg, 100mg film-coated tablets (Voydeya®)	2675	As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. **SMC restriction**: under the advice of the national PNH service.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
daridorexant 25mg, 50mg film-coated tablets (Quviviq®)	2611	Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. **SMC restriction**: in patients who have failed cognitive behavioural therapy for insomnia (CBT-I) or for whom CBT-I is unsuitable or unavailable.	Decision deferred to future meeting Updates decision 16/04/24	18/02/2025
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	2635	In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Routinely available in line with national guidance, SMC 2635 https://scottishmedicines.org.uk/media/8231/dostarlimab-jemperli-final-march-2024-for-website.pdf Updates decision 16/04/24	17/09/2024
drospirenone 4mg film-coated tablets (Slynd®)	2725	Contraception.	Not routinely available as not recommended for use in NHS Scotland, SMC 2725 https://scottishmedicines.org.uk/media/8640/drospirenone-slynd-non-sub-final-sept-2024-for-website.pdf	15/10/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
dupilumab 300mg solution for injection in pre-filled pen and syringe (Dupixent®)	2682	Treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2682 https://www.scottishmedicines.org.uk/media/8382/dupilumab-dupixent-non-sub-final-may-2024-for-website.pdf	18/06/2024
durvalumab 50 mg/mL concentrate for solution for infusion (Imfinzi®)	2734	In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/02/2025
durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®)	2677	In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements.	Not routinely available as not recommended for use in NHS Scotland, SMC 2677 https://scottishmedicines.org.uk/media/8810/durvalumab-imfinzi-final-nov-2024-for-website.pdf	21/01/2025
elranatamab 40mg/mL solution for injection (Elrexfio®)	2669	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/09/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
empagliflozin 10mg, 25mg film-coated tablets (Jardiance®)	2642	In adults for the treatment of chronic kidney disease. **SMC restriction**: in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment: • an estimated glomerular filtration rate (eGFR) of 20mL/min/1.73m^2 up to 45mL/min/1.73m^2, or • an eGFR of 45mL/min/1.73m^2 up to 90mL/min/1.73m^2 and either: o A urine albumin-to-creatinine ratio (uACR) of 22.6mg/mmol or more, or o Type 2 Diabetes Mellitus (T2DM)	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/08/2024
enzalutamide 40mg film-coated tablets (Xtandi®)	2742	As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2742 https://scottishmedicines.org.uk/media/8730/enzalutamide-xtandi-non-sub-final-oct-2024-for-website.pdf	19/11/2024
epcoritamab 4mg/0.8mL concentrate for solution for injection, 48mg solution for injection (Tepkinly®)	2632	As monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Routinely available in line with national guidance, SMC 2632 https://scottishmedicines.org.uk/media/8387/epcoritamab-tepkinly-final-may-2024-amended-050624-for-website.pdf Updates decision 18/06/24	21/01/2025
etranacogene dezaparvovec 1 x 10^13 genome copies/mL concentrate for solution for infusion (Hemgenix®)	2649	For the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Routinely available from a specialist centre in another health board	20/08/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
etrasimod 2mg film-coated tablets (Velsipity®)	2655	For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.	Decision deferred to future meeting Updates decision 18/06/24	21/01/2025
faricimab 120mg/mL solution for injection (Vabysmo®)	2685	Treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/10/2024
fenfluramine 2.2mg/mL oral solution (Fintepla®)	2723	Treatment of seizures associated with Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. **SMC restriction**: patients whose seizures have not been controlled after trying two or more anti-epileptic medicines.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/02/2025
fezolinetant 45mg film-coated tablets (Veoza®)	2702	Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.	Not routinely available as not recommended for use in NHS Scotland, SMC 2702 https://scottishmedicines.org.uk/media/8525/fezolinetant-veoza-non-sub-final-july-2024-for-website.pdf	20/08/2024
follitropin delta 12micrograms/0.36mL, 36micrograms/1.08mL, 72micrograms/2.16mL solution for injection in a pre-filled pen (Rekovelle®)	2670	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. **SMC restriction**: for use in normal responders (patients with an anti-Müllerian hormone level of >5.4 pmol/L) or high responders (patients with an anti-Müllerian hormone level of ≥25 pmol/L).	Routinely available in line with national guidance, SMC 2670 https://scottishmedicines.org.uk/media/8467/follitropin-delta-rekovelle-abb-final-june-2024-for-website.pdf Updates decision 20/08/24	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
glofitamab 1mg/mL concentrate for solution for infusion (Columvi®)	2614	As monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.	Routinely available in line with national guidance, SMC 2614 https://scottishmedicines.org.uk/media/8388/glofitamab-columvi-final-may-2024-amended-050624-for-website.pdf Updates decision 18/06/24	21/01/2025
Inaqovi® 35mg/100mg film coated tablets (decitabine/cedazuridine)	2681	As monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2681 https://www.scottishmedicines.org.uk/media/8381/decitabine-cedazuridine-inaqovi-non-sub-final-may-2024-for-website.pdf	18/06/2024
iptacopan 200mg hard capsules (Fabhalta®)	2676	As monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. **SMC restriction**: under the advice of the national PNH service.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
ivosidenib 250mg film-coated tablet (Tibsovo®)	2664	As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who were previously treated by at least one prior line of systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/09/2024
Kaftrio® 37.5mg/25mg/50mg, 75mg/50mg/100mg film coated tablets, 60mg/40mg/80mg, 75mg/50mg/100mg granules (elexacaftor/ivacaftor/tezacaftor)	2713	In a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 2 years to less than 6 years (granules in sachet) and 6 years and older (film-coated tablets) who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Routinely available in line with national guidance, NICE TA988 https://www.nice.org.uk/guidance/ta988 Updates decision 20/08/24	17/09/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
lebrikizumab 250mg solution for injection in pre-filled syringe or pen (Ebglyss®)	2707	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40kg who are candidates for systemic therapy. **SMC restriction**: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable and where a biologic would otherwise be offered.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
lecanemab 100mg/mL concentrate for solution for infusion (Leqembi®)	2700	For the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHS Scotland, SMC 2700 https://scottishmedicines.org.uk/media/8949/lecanemab-leqembi-final-jan-2025-amended-030225-070225-for-website.pdf	18/02/2025
Lecigon® 20mg/mL /5mg/mL / 20mg/mL intestinal gel (levodopa/carbidopa monohydrate/ entacapone)	2507	Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as not recommended for use in NHS Scotland, SMC 2507 https://scottishmedicines.org.uk/media/8807/levodopa-carbidopa-entacapone-lecigon-final-jan-2023-amended-071124-for-website.pdf	21/01/2025
lenacapavir 300mg film-coated tablets, 464mg solution for injection (Sunlenca®)	2691	**Film-coated tablets:** in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection. **Solution for injection**: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.	Not routinely available as not recommended for use in NHS Scotland, SMC 2691 https://www.scottishmedicines.org.uk/media/8457/lenacapavir-sunlenca-non-sub-final-june-2024-for-website.pdf	20/08/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
linzagolix 100mg, 200mg film-coated tablets (Yselty®)	2631	The treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. **SMC restriction**: for use in patients when conventional first-line treatments (such as tranexamic acid, hormonal contraceptives and intrauterine devices) have failed or are considered unsuitable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
Lonsurf® 15mg/6.14mg, 20mg/8.19mg film-coated tablets (trifluridine/tipiracil)	2654	In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.	Routinely available in line with national guidance, SMC 2654 https://scottishmedicines.org.uk/media/8523/trifluridine-tipiracil-lonsurf-final-july-2024-for-website.pdf Updates decision 20/08/24	15/04/2025
mavacamten 2.5mg, 5mg, 10mg, 15mg hard capsules (Camzyos®)	2618	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Routinely available in line with national guidance, SMC 2618 https://scottishmedicines.org.uk/media/8226/mavacamten-camzyos-final-march-2024-for-website.pdf Updates decision 16/04/24	18/03/2025
mirikizumab 100mg solution for injection in pre-filled pen, 300mg concentrate for solution for infusion (Omvoh®)	2650	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Routinely available in line with local guidance Updates decision 16/04/24	20/08/2024
momelotinib 100mg, 150mg, 200mg film coated tablet (Omjjara®)	2636	Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Routinely available in line with national guidance, SMC 2636 https://scottishmedicines.org.uk/media/8384/momelotonib-omjjara-abb-final-may-2024-for-website.pdf Updates decision 18/06/24	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2704	Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma.	Not routinely available as not recommended for use in NHS Scotland, SMC 2704 https://scottishmedicines.org.uk/media/8520/nivolumab-opdivo-non-sub-final-july-2024-for-website.pdf	20/08/2024
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2726	In combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.	Not routinely available as not recommended for use in NHS Scotland, SMC 2726 https://scottishmedicines.org.uk/media/8642/nivolumab-opdivo-final-sept-2024-for-website.pdf	15/10/2024
olaparib 100mg, 150mg film-coated tablets (Lynparza®)	2737	Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/02/2025
Opdualag® 240mg/80mg concentrate for solution for infusion (nivolumab/relatlimab)	2645	First-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/08/2024
Orkambi® 100mg/125mg, 200mg/125mg film-coated tablets, 75mg /94mg, 100mg/125mg, 150mg/188mg granules in sachets (lumacaftor/ivacaftor)	2712	The treatment of cystic fibrosis (CF) in patients aged 1 year and older (granules in sachet) or 6 years and older (film-coated tablets) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Routinely available in line with national guidance, NICE TA988 https://www.nice.org.uk/guidance/ta988 Updates decision 20/08/24	17/09/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
pegcetacoplan 1,080mg solution for infusion (Aspaveli®)	2715	As monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.	Not routinely available as not recommended for use in NHS Scotland, SMC 2715 https://scottishmedicines.org.uk/media/8571/pegcetacoplan-aspaveli-non-sub-final-august-2024-for-website.pdf	17/09/2024
pegunigalsidase alfa 2mg/mL concentrate for solution for infusion (Elfabrio®)	2665	For long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase). **SMC restriction**: for use in adults with symptomatic Fabry disease who would usually be offered an enzyme replacement therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/08/2024
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2644	In combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.	Not routinely available as not recommended for use in NHS Scotland, SMC 2644 https://www.scottishmedicines.org.uk/media/8460/pembrolizumab-keytruda-mgc-final-june-2024-for-website.pdf	20/08/2024
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2660	In combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.	Routinely available in line with national guidance, SMC 2660 https://scottishmedicines.org.uk/media/8461/pembrolizumab-keytruda-final-june-2024-for-website.pdf Updates decision 20/08/24	18/02/2025
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2683	In combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.	Not routinely available as not recommended for use in NHS Scotland, SMC 2683 https://www.scottishmedicines.org.uk/media/8385/pembrolizumab-keytruda-non-sub-final-may-2024-for-website.pdf	18/06/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2688	In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.	Not routinely available as not recommended for use in NHS Scotland, SMC 2688 https://scottishmedicines.org.uk/media/8733/pembrolizumab-keytruda-final-oct-2024-for-website.pdf	19/11/2024
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2689	As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy. **SMC restriction**: adults whose tumours express programmed death-ligand 1 (PD-L1) with less than 50% (0 to 49%) tumour proportion score (TPS).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/10/2024
Pylera® 140mg/125mg/125mg hard capsules (bismuth subcitrate potassium/ metronidazole/ tetracycline hydrochloride)	2701	In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers. **SMC restriction**: restricted to use in accordance with clinical guidelines for the eradication of H. pylori.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
quizartinib 17.7mg, 26.5mg film-coated tablets (Vanflyta®)	2699	In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
relugolix 120mg film-coated tablets (Orgovyx®)	2678	- for the treatment of adult patients with advanced hormone-sensitive prostate cancer - for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/10/2024
remdesivir 100mg powder for concentrate for solution for infusion (Veklury®)	2550	Treatment of COVID-19 in: • adults and paediatric patients (at least 4 weeks of age and weighing at least 3kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment) • adults and paediatric patients (weighing at least 40kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 **SMC restriction**: as an option for treating COVID-19 in hospitals in: • adults only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19). • babies, children and young people, only if they: - are aged 4 weeks to 17 years and weigh at least 3kg, and have pneumonia and need supplemental oxygen, or - weigh at least 40kg and have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19)	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/05/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
remimazolam 50mg powder for concentrate for solution for injection/infusion (Byfavo®)	2692	In adults for intravenous induction and maintenance of general anaesthesia.	Not routinely available as not recommended for use in NHS Scotland, SMC 2692 https://www.scottishmedicines.org.uk/media/8462/remimazolam-byfavo-non-sub-final-june-2024-for-website.pdf	20/08/2024
rezafungin acetate 200mg powder for concentrate for solution for infusion (Rezzayo®)	2659	For the treatment of invasive candidiasis in adults. **SMC restriction**: use should be on the advice of local microbiologists or specialists in infectious disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/10/2024
ripretinib 50mg tablets (Qinlock®)	2722	For the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Not routinely available as not recommended for use in NHS Scotland, SMC 2722 https://scottishmedicines.org.uk/media/9017/ripretinib-tablets-qinlock-final-feb-2025-for-website.pdf	18/03/2025
risankizumab 180mg, 360mg solution for injection in cartridge, 600mg concentrate for solution for infusion (Skyrizi®)	2686	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
ritlecitinib tosylate 50mg hard capsules (Litfulo®)	2610	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Routinely available in line with national guidance, SMC 2610 https://scottishmedicines.org.uk/media/8228/ritlecitinib-litfulo-final-march-2024-for-website.pdf Updates decision 16/04/24	15/10/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Roclanda® 50micrograms/mL / 200micrograms/mL eye drops, solution (latanoprost/netarsudil)	2720	For the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. **SMC restriction**: for use in patients for whom treatment with a prostaglandin analogue alone provides insufficient IOP reduction, only if: - the patient has then tried a fixed-dose combination treatment and it has not sufficiently reduced IOP, or - a fixed-dose combination treatment containing beta-blockers is unsuitable	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/02/2025
rozanolixizumab 140mg/mL solution for injection (Rystiggo®)	2761	As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.	Not routinely available as not recommended for use in NHS Scotland, SMC 2761 https://scottishmedicines.org.uk/media/8853/rozanolixizumab-rystiggo-non-sub-final-dec-2024-for-website.pdf	21/01/2025
ruxolitinib 15mg/g cream (Opzelura®)	2634	For the treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.	Not routinely available as not recommended for use in NHS Scotland, SMC 2634 https://www.scottishmedicines.org.uk/media/8317/ruxolitinib-topical-opzelura-final-april-2024-amended-080524-for-website.pdf	21/05/2024
Ryeqo® 40mg/1mg/0.5mg film-coated tablets (relugolix/ estradiol/ norethisterone acetate	2666	In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
selinexor 20mg film-coated tablets (Nexpovio®)	2673	In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/10/2024
selinexor 20mg film-coated tablets (Nexpovio®)	2674	In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. **SMC restriction**: restricted for use in patients with lenalidomide-refractory multiple myeloma, and where an anti-CD38 monoclonal antibody is not appropriate.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	15/10/2024
sirolimus 2mg/g gel (Hyftor®)	2710	For the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
somapacitan 10mg/1.5mL, 15mg/1.5mL solution for injection in pre-filled pen (Sogroya®)	2629	For the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD). **SMC restriction**: for children aged 3 years and above and adolescents with growth failure due to growth hormone deficiency (paediatric GHD).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
spesolimab 450mg concentrate for solution for infusion (Spevigo®)	2729	For the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2729 https://scottishmedicines.org.uk/media/9018/spesolimab-spevigo-final-feb-2025-for-website.pdf	18/03/2025
Symbicort® Turbohaler® 200micrograms/6micrograms/ inhalation, inhalation powder (budesonide/formoterol fumarate)	2622	As reliever therapy for adults and adolescents (12 years and older) with mild asthma. **SMC restriction**: for use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.	Routinely available in line with local guidance	21/05/2024
Symkevi® 50mg/75mg, 100mg/150mg film-coated tablets (tezacaftor/ivacaftor)	2711	In a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.	Routinely available in line with national guidance, NICE TA988 https://www.nice.org.uk/guidance/ta988 Updates decision 20/08/24	17/09/2024
talazoparib 0.1mg, 0.25mg, 1mg hard capsules (Talzenna®)	2753	In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/03/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
talquetamab 2mg/mL, 40mg/mL solution for injection (Talvey®)	2705	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2705 https://scottishmedicines.org.uk/media/8521/talquetamab-talvey-non-sub-final-july-2024-for-website.pdf	20/08/2024
teclistamab 10mg/mL, 90mg/mL solution for injection (Tecvayli®)	2668	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/09/2024
tenecteplase 5,000 units (25mg) powder for solution for injection (Metalyse®)	2697	In adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.	Routinely available in line with national guidance, SMC 2697 https://scottishmedicines.org.uk/media/8727/tenecteplase-metalyse-abbreviated-final-oct-2024-for-website.pdf Updates decision 19/11/24	21/01/2025
tirzepatide 2.5mg, 5mg, 7.5mg, 10mg, 12,5mg, 15mg solution for injection in pre-filled pen (Mounjaro®)	2633	For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in addition to other medicinal products for the treatment of diabetes. **SMC restriction:** in addition to other oral anti-diabetic medicines as an option when glucagon-like peptide-1 (GLP-1) receptor agonists would be considered.	Routinely available in line with local guidance, ADVICE ARCHIVED, replaced by FG advice published 01/07/2024 (FG meeting 18/06/2024). Updates decision 16/04/24	18/06/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tirzepatide 2.5mg, 5mg, 7.5mg, 10mg, 12,5mg, 15mg solution for injection in pre-filled pen (Mounjaro®)	2653	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30kg/m^2 (obesity) or ≥27kg/m^2 to <30kg/m^2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). **SMC restriction**: for use in adults with BMI ≥30kg/m^2* and at least one weight-related comorbidity. *a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.	Not routinely available as local implementation plans are being developed	18/06/2024
tixagevimab 150mg/mL plus cilgavimab 150mg/mL solution for injection (Evusheld®)	2558	Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Not routinely available as not recommended for use in NHS Scotland, NICE TA971 https://www.nice.org.uk/guidance/TA971	21/05/2024
trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)	2693	As monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.	Not routinely available as not recommended for use in NHS Scotland, SMC 2693 https://www.scottishmedicines.org.uk/media/8463/trastuzumab-deruxtecan-enhertu-non-sub-final-june-2024-for-website.pdf	20/08/2024
trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)	2706	As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2706 https://scottishmedicines.org.uk/media/8522/trastuzumab-deruxtecan-enhertu-non-sub-final-july-2024-amended-070824-for-website.pdf	20/08/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ublituximab 150mg concentrate for solution for infusion (Briumvi®)	2731	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. **SMC restriction**: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
vamorolone 40mg/mL oral suspension (Agamree®)	2721	Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
vibegron 75mg film-coated tablets (Obgemsa®)	2696	Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
volanesorsen 285mg solution for injection in pre-filled syringe (Waylivra®)	2716	As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.	Not routinely available as not recommended for use in NHS Scotland, SMC 2716 https://scottishmedicines.org.uk/media/8573/volanosorsen-waylivra-non-sub-final-august-2024-for-website.pdf	17/09/2024
voretigene neparvovec 5 x 10^12 vector genomes/mL concentrate and solvent for solution for injection (Luxturna®)	2641	For the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.	Routinely available from a specialist centre in another health board	20/08/2024
voxelotor 500mg film-coated tablets (Oxbryta®)	2626	Treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide. **SMC restriction**: as a second line treatment for haemolytic anaemia in patients with SCD who are intolerant, ineligible or have an inadequate response to, hydroxycarbamide.	This medicine is now withdrawn from use/discontinued as a precautionary measure while a review of the benefits and risks is carried out. Updates decision 18/06/24	15/10/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
zanubrutinib 80mg hard capsules (Brukinsa®)	2671	In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	Not routinely available as not recommended for use in NHS Scotland, SMC 2671 https://www.scottishmedicines.org.uk/media/8312/zanubrutinib-brukinsa-non-sub-final-april-2024-for-website.pdf	21/05/2024
zanubrutinib 80mg hard capsules (Brukinsa®)	2684	As monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.	Routinely available in line with national guidance, SMC 2684 https://scottishmedicines.org.uk/media/8809/zanubrutinib-brukinsa-final-nov-2024-for-website.pdf Updates decision 21/01/25	15/04/2025
zilucoplan 16.6mg, 23mg, 32.4mg solution for injection in pre-filled syringe (Zilbrysq®)	2717	As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti acetylcholine receptor (AChR) antibody positive.	Not routinely available as not recommended for use in NHS Scotland, SMC 2717 https://scottishmedicines.org.uk/media/8574/zilucoplan-zilbrysq-non-sub-final-august-2024-for-website.pdf	17/09/2024